drugset / Trial / NCT03700450
Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma
Phase 2
Completed
37 enrolled
University Medical Center Hamburg-Eppendorf
Esteve Pharmaceuticals GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD and progression-free survival at 2 years after after allogeneic stem cell transplantation for patients with multiple myeloma.
Timeline
- Start
- 2018-03-16
- Primary completion
- 2022-11-22
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |